Eisai Taps Continuous Manufacturing for Tazverik, Eyes Its Use for Other Oncology Assets Too

CTS-MiGRA Continuous Manufacturing System (Courtesy of Eisai) In what could be the first such move among Japanese drug makers, Eisai is adopting continuous manufacturing in the commercial production of a pharmaceutical product. The company’s attempt starts with Tazverik (tazemetostat), a...read more